For the Inventor, By the Inventor

Enter assignee name

Poxel Sa

USPTO Granted Patents = 12

EPO Patents = 4

Forward Citations = 2

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Vincent Jacques (6 out of 30 patents)

Sheila DeWitt (5 out of 21 patents)

Sébastien Bolze (4 out of 11 patents)

4. Leonardus Van Der Ploeg (4 out of 4 patents)

5. Anthony W Czarnik (3 out of 32 patents)

6. Laure Françoise Valérie Navarre (2 out of 2 patents)

7. Bill Symonds (2 out of 2 patents)

8. Steve Piscitelli (2 out of 2 patents)

9. Karen Segal (2 out of 2 patents)

10. Ruby Holder (2 out of 2 patents)

11. Sophie Bozec (2 out of 2 patents)

12. Pascale Fouqueray (2 out of 2 patents)

13. Christophe Arbet-Engels (2 out of 2 patents)

14. Julie Dubourg (2 out of 2 patents)

15. Paul Strumph (2 out of 4 patents)

12 patents: Sort by Forward Citations

1. 12036226 - Methods of treating subjects having diabetes with chronic kidney disease (2024-07-16),

2. 11918569 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2024-03-05),

3. 11918567 - Deuterium-enriched pioglitazone (2024-03-05),

4. 11767317 - Methods of synthesizing enantiopure deuterium-enriched pioglitazone (2023-09-26),

5. 11617754 - Methods of treating heart failure with preserved ejection fraction (2023-04-04),

6. 11319313 - Crystalline forms of deuterium-enriched pioglitazone (2022-05-03),

7. 11266652 - Methods of treating subjects having diabetes with chronic kidney disease (2022-03-08),

8. 11141411 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2021-10-12),

9. 11123336 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2021-09-21),

10. 10940143 - Deuterium-enriched pioglitazone (2021-03-09),

11. 10576071 - Deuterium-enriched pioglitazone (2020-03-03),

12. 10265305 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2019-04-23),

Poxel SA is a biopharmaceutical company based in Lyon, France, specializing in the development of innovative treatments for metabolic diseases, particularly diabetes and obesity. The company focuses on advancing its proprietary drug candidates through rigorous research and clinical development, leveraging its expertise in pharmacology and metabolic science. Poxel is committed to addressing unmet medical needs and improving patient outcomes by harnessing cutting-edge technology and scientific knowledge in the field of metabolic disorders.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

12 Patents

#33 in Lyon

#1,481 in France

#48,090 in the World

Poxel Sa

Forward Citations = 2

19 inventors:

Vincent Jacques (6 out of 30 patents)

Sheila DeWitt (5 out of 21 patents)

Sébastien Bolze (4 out of 11 patents)

4. Leonardus Van Der Ploeg (4 out of 4 patents)

5. Anthony W Czarnik (3 out of 32 patents)

Please report any incorrect information to [email protected]

Loading…